High population of live bacterial strains, resistant to stomach acids, bile salts and pancreatic enzymes, in appropriate proportions, compatibility and synergistic action aimed at protecting the gastrointestinal system during the period of antibiotics. Probiotics intake during antibiotic therapy is associated with a reduced risk of developing diarrhea. In cases of strong antibiotics, such as H.pylori’s triple antibiotic therapy, probiotics can also reduce serious diarrhea side effects. 

Kluyveromyces marxianus B0399 is a new generation probiotic with natural antibiotic resistance, which makes Kluyveromyces marxianus B0399 an ideal probiotic for the period of antibiotics. K.marxianus B0399® demonstrates a number of beneficial and strain specific properties desirable for application as a probiotic. 

Postbiotics are heat inactivated bacterial, which are recognized and contribute to the normal immune and inflammatory response of the body. The patented strain of Lactobacillus rhamnosus CRL1505™ HI is scientifically studied for its positive effect on reducing the intensity and duration of symptoms associated with respiratory infections.